Immunic (IMUX) Other Accumulated Expenses (2013 - 2026)

Immunic has reported Other Accumulated Expenses for 14 years, with the latest figure at $4.9 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 280.8% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 280.8% YoY) and the FY2025 annual result came in at $1.8 million, up 29.59% from the prior year.
• Other Accumulated Expenses climbed to $4.9 million in Q1 2026 per IMUX's latest filing, from $1.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $4.9 million in Q1 2026 and troughed at $544000.0 in Q2 2022.
• A 5-year average of $1.3 million and a median of $966000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses slumped 86.83% in 2022, then surged 280.8% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $810000.0 in 2022, then rose by 19.26% to $966000.0 in 2023, then surged by 46.58% to $1.4 million in 2024, then rose by 29.59% to $1.8 million in 2025, then soared by 168.12% to $4.9 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $4.9 million, $1.8 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.